Literature DB >> 7692913

Inhibition of murine intestinal inflammation by anti-substance P antibody.

A Agro1, A M Stanisz.   

Abstract

Several neuropeptides have recently been shown to affect various aspects of the inflammatory process. Among these, the neuropeptide substance P possesses a host of immune modifying actions, which include the enhancement of lymphocyte activity, macrophage function, and neutrophil chemotaxis. The role of substance P during inflamed states has, as yet, not been fully described. Here, in T. spiralis-infected mice, we parallel increased levels of substance P both locally, (the gut) and peripherally (serum) with decreased lymphocyte responsiveness. Upon the introduction of in vivo antisubstance P antibody during the infection, levels of substance P, gastrointestinal inflammation, and lymphocyte proliferation are significantly restored to baseline (noninfected) levels. These findings suggest that the neuropeptide substance P plays an important role in promoting inflammation. It also offers the basis for future pharmacological interventions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692913

Source DB:  PubMed          Journal:  Reg Immunol        ISSN: 0896-0623


  10 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome.

Authors:  Bin Feng; Jun Ho La; Erica S Schwartz; G F Gebhart
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.

Authors:  R A Tripp; D Moore; J Winter; L J Anderson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 3.  Neuroimmune mechanisms in health and disease: 2. Disease.

Authors:  H Anisman; M G Baines; I Berczi; C N Bernstein; M G Blennerhassett; R M Gorczynski; A H Greenberg; F T Kisil; R D Mathison; E Nagy; D M Nance; M H Perdue; D K Pomerantz; E R Sabbadini; A Stanisz; R J Warrington
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

4.  Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation.

Authors:  T Goode; J O'Connell; P Anton; H Wong; J Reeve; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

5.  Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidium parvum.

Authors:  Ioana M Sonea; Mitchell V Palmer; Dhuha Akili; James A Harp
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  TGF-beta regulates T-cell neurokinin-1 receptor internalization and function.

Authors:  Martin Beinborn; Arthur Blum; Long Hang; Tommy Setiawan; Jonathan C Schroeder; Korynn Stoyanoff; John Leung; Joel V Weinstock
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 7.  Substance P, obesity, and gut inflammation.

Authors:  Iordanes Karagiannides; Charalabos Pothoulakis
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-02       Impact factor: 3.243

8.  Accumulation of nerve growth factor and its receptors in the uterus and dorsal root ganglia in a mouse model of adenomyosis.

Authors:  Yan Li; Shao-fen Zhang; Shi-en Zou; Xian Xia; Lei Bao
Journal:  Reprod Biol Endocrinol       Date:  2011-03-08       Impact factor: 5.211

Review 9.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

Review 10.  The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders.

Authors:  M Brittany Johnson; Ada D Young; Ian Marriott
Journal:  Front Cell Neurosci       Date:  2017-01-04       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.